Filters








74 Hits in 2.5 sec

AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON THE BRAIN SURFACE

Vincent Dore, Pierrick Bourgeat, Samantha C. Burnham, Ralph N. Martins, Colin L. Masters, David Ames, Christopher C. Rowe, Olivier Salvado, Jurgen Fripp, Victor L. Villemagne
2019 Alzheimer's & Dementia  
Background: In the recent years, there has been an increasing number of tau imaging studies, mainly with 18F-AV1451 and 18F-MK6240 tracers.  ...  Methods: Two hundred and forty-three participants from the AIBL study underwent tau imaging with either 18F-AV1451 (n¼83) or 18F-MK6240 (n¼140).  ... 
doi:10.1016/j.jalz.2019.06.4811 fatcat:4tb2henevjdwrlslpllskpv4ae

Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients

Qian Zhao, Min Liu, Lingxia Ha, Yun Zhou, Alzheimer's Disease Neuroimaging Initiative
2019 Frontiers in Neurology  
PVC did improve the results of tau deposition and correlation studies in small brain regions and suggest to be routinely used in 18F-AV1451 tau PET quantification.  ...  Among the tau PET molecular probes, 18F-AV1451 is characterized by high selectivity for pathologic tau aggregates over amyloid plaques, limited non-specific binding in white and gray matter, and confined  ...  PVC did improve the results of tau deposition and correlation studies in small brain regions and is suggested to be routinely used in 18 F-AV1451 tau PET quantification.  ... 
doi:10.3389/fneur.2019.00486 pmid:31156534 pmcid:PMC6530456 fatcat:dgnjidh6hvcnte36jqg5xwubtu

Tau PET imaging in neurodegenerative tauopathies—still a challenge

Antoine Leuzy, Konstantinos Chiotis, Laetitia Lemoine, Per-Göran Gillberg, Ove Almkvist, Elena Rodriguez-Vieitez, Agneta Nordberg
2019 Molecular Psychiatry  
Lastly, methodological considerations for the quantification of in vivo ligand binding are addressed, along with potential future applications of tau PET, including therapeutic trials.  ...  including first- (e.g., [18F]THK5317, [18F]THK5351, [18F]AV1451, and [11C]PBB3) and second-generation compounds [namely [18F]MK-6240, [18F]RO-948 (previously referred to as [18F]RO69558948), [18F]PI-2620  ...  authors contributed equally: Antoine Leuzy, Konstantinos Chiotis Acknowledgements The authors wish to thank the following individuals for providing images or the chemical structures of secondgeneration tau  ... 
doi:10.1038/s41380-018-0342-8 pmid:30635637 pmcid:PMC6756230 fatcat:hj4z7l3hnbasfkb32gzplmfoo4

AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON BRAIN SURFACE

Vincent Dore, Pierrick Bourgeat, Samantha C. Burnham, Ralph N. Martins, Colin L. Masters, David Ames, Christopher C. Rowe, Olivier Salvado, Jurgen Fripp, Victor L. Villemagne
2019 Alzheimer's & Dementia  
By autoradiography, 18 F-AV-1451 binding is observed only on tau rich AD tissue and not on normal control tissue when stringent wash conditions are used (i.e. 30% and 70% EtOH) .  ...  , the weak inhibition by AV-1451 of safinamide: MAO-B binding, and the reported lack of effect of MAO-B inhibitor treatment on 18 F-AV-1451 PET signal in patients treated with selegiline or rasagiline.  ...  Methods: Two hundred and forty-three participants from the AIBL study underwent tau imaging with either 18F-AV1451 (n¼83) or 18F-MK6240 (n¼140).  ... 
doi:10.1016/j.jalz.2019.06.4282 fatcat:x3x4nroyzzgfdcvjoofkrp3rui

EVALUATION OF TAU DEPOSITION IN AMYLOID-POSITIVE MCI OR MILD AD DEMENTIA SUBJECTS FROM THE ELENBECESTAT MISSION AD PROGRAM USING [18 F]PI-2620 PET

Andrew Wills Stephens, Santiago Bullich, Andre Mueller, Mathias Berndt, Susan de Santi, David Scott, Kate Adamczuk, Joyce Suhy, June Kaplow, Stephen Krause, Julia Chang, Bruce Albala (+1 others)
2019 Alzheimer's & Dementia  
Background: In the recent years, there has been an increasing number of tau imaging studies, mainly with 18F-AV1451 and 18F-MK6240 tracers.  ...  Methods: Two hundred and forty-three participants from the AIBL study underwent tau imaging with either 18F-AV1451 (n¼83) or 18F-MK6240 (n¼140).  ... 
doi:10.1016/j.jalz.2019.06.4810 fatcat:qwadg4if7zexxjcx7qn6urjlxu

ISSUES REGARDING [18F]MK6240 REFERENCE REGION SELECTION BASED ON THE FULL KINETIC MODELING

Min Su Kang, Tharick A. Pascoal, Monica Shin, Mira Chamoun, Sulantha Mathotaarachchi, Andrea Lessa Benedet, Joseph Therriault, Melissa Savard, Reda Bouhachi, Chris Hsiao, Emilie Thomas, Daniel Chartrand (+6 others)
2019 Alzheimer's & Dementia  
Background: In the recent years, there has been an increasing number of tau imaging studies, mainly with 18F-AV1451 and 18F-MK6240 tracers.  ...  Methods: Two hundred and forty-three participants from the AIBL study underwent tau imaging with either 18F-AV1451 (n¼83) or 18F-MK6240 (n¼140).  ... 
doi:10.1016/j.jalz.2019.06.4283 fatcat:33uvoat6y5axrn5pzlgv24b62u

EARLY ADULTHOOD VASCULAR RISK STRONGLY PREDICTS BRAIN VOLUMES AND WHITE MATTER DISEASE, BUT NOT AMYLOID STATUS, AT AGE 69-71 YEARS: EVIDENCE FROM A BRITISH BIRTH COHORT

Christopher A. Lane, Jo Barnes, Jennifer M. Nicholas, Thomas D. Parker, Ashvini Keshavan, Sarah M. Buchanan, Sarah E. Keuss, Carole H. Sudre, David M. Cash, Ian B. Malone, Sarah-Naomi James, Andrew Wong (+3 others)
2019 Alzheimer's & Dementia  
Background: In the recent years, there has been an increasing number of tau imaging studies, mainly with 18F-AV1451 and 18F-MK6240 tracers.  ...  Methods: Two hundred and forty-three participants from the AIBL study underwent tau imaging with either 18F-AV1451 (n¼83) or 18F-MK6240 (n¼140).  ...  Participants undertook combined MR/florbetapir amyloid PET scanning in 2015-2018, aged 69-71 years.  ... 
doi:10.1016/j.jalz.2019.06.4812 fatcat:5g7uqr4v3bdena27nvpcloityq

Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography

Elijah Mak, Nicolas Nicastro, Maura Malpetti, George Savulich, Ajenthan Surendranathan, Negin Holland, Luca Passamonti, Simon P. Jones, Stephen F. Carter, Li Su, Young T. Hong, Tim D. Fryer (+4 others)
2020 Neurobiology of Aging  
Tau deposition was quantified using [18F]-AV1451 positron emission tomography in people with DLB (n = 10), AD (n = 27), and healthy controls (n = 14).  ...  There was a high degree of colocalization between [18F]-AV1451 and [11C]-PK11195 binding (p < 0.001). Our findings of minimal tau burden in DLB confirm previous studies.  ...  The authors thank the radiographers and technologists at the Wolfson Brain Imaging Center and PET/CT Unit, Cambridge University Hospital, for their invaluable support in data acquisition.  ... 
doi:10.1016/j.neurobiolaging.2020.11.006 pmid:33631469 pmcid:PMC8209140 fatcat:ktfxlziosfgqvlso5lejbsptdi

Quantification of Tau Load Using [18F]AV1451 PET

Sandeep S. V. Golla, Tessa Timmers, Rik Ossenkoppele, Colin Groot, Sander Verfaillie, Philip Scheltens, Wiesje M. van der Flier, Lothar Schwarte, Mark A. Mintun, Michael Devous, Robert C. Schuit, Albert D. Windhorst (+4 others)
2017 Molecular Imaging and Biology  
Purpose: The tau tracer [ 18 F]AV1451, also known as flortaucipir, is a promising ligand for imaging tau accumulation in Alzheimer's disease (AD).  ...  Procedures: Following intravenous injection of 225 ± 16 MBq [ 18 F]AV1451, 130 min dynamic PET scans were performed in five biomarker confirmed AD patients and five controls.  ...  In [ 18 F]AV1451 studies published previously Golla S.S.V. et al.: [ 18 F]AV1451 PET Quantification  ... 
doi:10.1007/s11307-017-1080-z pmid:28374171 pmcid:PMC5662681 fatcat:bdcbutqsp5cchp46k3nzjz24nu

Tau PET imaging with 18F-PI-2620 in patients with Alzheimer's disease and healthy controls: a first-in-human study

Andre Mueller, Santiago Bullich, Olivier Barret, Jennifer Madonia, Mathias Berndt, Caroline Papin, Audrey Perrotin, Norman Koglin, Heiko Kroth, Andrea Pfeifer, Gilles Tamagnan, John P Seibyl (+4 others)
2019 Journal of Nuclear Medicine  
tau PET tracer.  ...  18F-PI-2620 is a PET tracer with high binding affinity for aggregated tau, a key pathologic feature of Alzheimer disease (AD) and other neurodegenerative disorders.  ...  For personal use only. jnm.snmjournals.org Downloaded from F-PI-2620 TAU PET IN HUMANS • Mueller et al. F-PI-2620 TAU PET IN HUMANS • Mueller et al.  ... 
doi:10.2967/jnumed.119.236224 pmid:31712323 pmcid:PMC7262222 fatcat:ercpz5yzgfhu7nbwmnxt2bmypq

Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer's Disease

Zhen Qiao, Guihong Wang, Xiaobin Zhao, Kai Wang, Di Fan, Qian Chen, Lin Ai
2022 Frontiers in Aging Neuroscience  
All participants underwent 18F-FDG and 18F-AV1451 PET/CT. Clinical data and neuropsychological scores were collected.  ...  and tau protein deposition or glucose metabolism using 18F-FDG and 18F-AV1451 positron emission tomography/computed tomography (PET/CT).MethodsSixty-four patients with β-amyloid-positive (Aβ+) AD and  ...  Nevertheless, tau PET imaging is not only a mirror image of glucose metabolism.  ... 
doi:10.3389/fnagi.2022.841942 pmid:35663582 pmcid:PMC9158435 fatcat:4ftunqaapna63cotdwubhjgrg4

Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease

Melanie Dani, Melanie Wood, Ruth Mizoguchi, Zhen Fan, Zuzana Walker, Richard Morgan, Rainer Hinz, Maya Biju, Tarun Kuruvilla, David J Brooks, Paul Edison
2018 Brain  
We thank GE Healthcare for the provision of 18 Fflutemetamol and Avid pharmaceuticals for use of the radiotracer 18 F-AV1451.  ...  Acknowledgements The authors thank Imanova Centre for Imaging Sciences for the provision of 11 C-PBR28, scanning and blood analysis equipment, and the Imperial College Clinical Imaging Facility for PET  ...  For 18F-flutemetamol and 11C-PBR28, a threshold of significance of p<0.05 was used. For 18F-AV1451, a threshold of significance of p<0.01 was used.  ... 
doi:10.1093/brain/awy188 pmid:30052812 fatcat:miw6loyorrbi7bhrvxtjhsf7za

Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local β-amyloid, Tau, and APOE4

Frances C. Quevenco, Jiri M. van Bergen, Valerie Treyer, Sandro T. Studer, Sonja M. Kagerer, Rafael Meyer, Anton F. Gietl, Philipp A. Kaufmann, Roger M. Nitsch, Christoph Hock, Paul G. Unschuld
2020 Frontiers in Aging Neuroscience  
AV-1451 PET for tau.  ...  Methods: Fifty-seven cognitively unimpaired old-aged adults (MMSE = 29.20 ± 1.11; 73 ± 8.32 years) were administered 11C Pittsburgh Compound B and 18F Flutemetamol PET for assessing β-amyloid, and 18F  ...  of Tau Load The current study also included measures of tau load, by assessing local retention of 18F-AV1451 using an established PET procedure (Chien et al., 2013) .  ... 
doi:10.3389/fnagi.2020.00046 pmid:32210782 pmcid:PMC7075450 fatcat:7l42fmxeuffz3mpsmbckpf5mxu

Longitudinal trajectories of amyloid deposition, cortical thickness, and tau in Down syndrome: A deep-phenotyping case report

Elijah Mak, Anastasia Bickerton, Concepcion Padilla, Madeleine J. Walpert, Tiina Annus, Liam R. Wilson, Young T. Hong, Tim D. Fryer, Jonathan P. Coles, Franklin I. Aigbirhio, Bradley T. Christian, Benjamin L. Handen (+5 others)
2019 Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring  
Multimodal neuroimaging, including three serial scans of [11C]-PiB-PET, four structural magnetic resonance imagings, as well as a [18F]-AV1451 scan, was interpreted alongside detailed neuropsychological  ...  Until now, data on the longitudinal trajectories of amyloid accumulation, tau pathology, and brain atrophy over multiple time points remain scarce in DS.  ...  Acknowledgments The research team thank the PET imaging technologist, MR radiographers, technicians, and radiochemists at the Wolfson Brain Imaging Centre, together with clinicians for their help in acquiring  ... 
doi:10.1016/j.dadm.2019.04.006 pmid:31909173 pmcid:PMC6939035 fatcat:2nqmanm5u5bknhsfz2oyp3gh4u

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Gérard N Bischof, Alessandra Dodich, Marina Boccardi, Thilo van Eimeren, Cristina Festari, Henryk Barthel, Oskar Hansson, Agneta Nordberg, Rik Ossenkoppele, Osama Sabri, B Frisoni G Giovanni, Valentina Garibotto (+1 others)
2021 European Journal of Nuclear Medicine and Molecular Imaging  
issues from the tau PET tracer of the first generation.  ...  Here, we use this framework to examine the translatability of the second-generation tau PET tracers into the clinical context.  ...  PET tracer (i.e., 18 F-RO-948) to other biomarkers assessing the same pathology (e.g., CSF measures of phosphorylated tau (p-tau) or to a first-generation tau PET tracer 18 F-AV1451).  ... 
doi:10.1007/s00259-020-05156-4 pmid:33590274 fatcat:c2ay7h2efnagvfdlxjkmulmwla
« Previous Showing results 1 — 15 out of 74 results